Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Real‐life data on newer biological and biosimilar agents for moderate‐to‐severe psoriasis are lacking. To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). The DERMBIO registry contains data on all Danish patients with moderate‐to‐severe plaque psoriasis...